LENZ Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. LENZ is a late-stage biopharmaceutical company developing ophthalmic treatments, principally LNZ100 for presbyopia. It has no approved products and reported no product revenue. The quarter includes Graphite’s results only from the March 21 merger closing; prior periods reflect LENZ OpCo alone, limiting comparability.
Financial results and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Research and development expense | $10.5 million | $10.3 million |
| Selling, general and administrative expense | $5.6 million | $2.3 million |
| Total operating expenses | $16.1 million | $12.6 million |
| Other expense, net | $0.6 million | $0.1 million |
| Net loss | $16.6 million | $12.7 million |
| Net loss per share, basic and diluted | $3.53 | $6.50 |
| Net cash used in operating activities | $23.9 million | $12.8 million |
- At March 31, cash and cash equivalents were $200.4 million, marketable securities were $12.9 million, and restricted cash was $0.1 million. Total cash, cash equivalents and marketable securities available for operations were $213.3 million.
- Total assets were $217.3 million, total liabilities $19.2 million, and stockholders’ equity $198.2 million. The filing reports no debt.
- Financing cash flow was $171.3 million, including $117.8 million in cash acquired in the merger and $53.5 million of gross PIPE proceeds. Investing cash flow was $18.0 million, primarily from securities maturities.
- No meaningful operating margin is available because the company reported no product revenue. The reported per-share loss is affected by merger-related share conversions and issuances; the filing notes weighted-average shares were retroactively recast.
Changes and notable items
- SG&A rose $3.3 million, or 142%, mainly from higher legal and professional fees, increased employee costs, merger-related option-vesting acceleration, and sales infrastructure and marketing spending.
- R&D increased $0.2 million, or 2%. Higher personnel and other development costs were largely offset by lower clinical trial and manufacturing costs as Phase 3 CLARITY trials wound down and were substantially completed in March.
- Other expense included a $1.0 million noncash increase in the fair value of preferred stock warrants before they were converted to common-stock warrants and reclassified to equity at merger closing. Interest income was $0.8 million.
- The March 21 reverse merger converted LENZ OpCo’s preferred and common securities into public-company common shares. The concurrent PIPE issued 3.56 million shares at $15.0299 per share. The company began trading as LENZ on Nasdaq on March 22.
Outlook, risks and contingencies
- Management planned to submit an NDA for LNZ100 to the FDA in mid-2024 and targeted a launch in the second half of 2025, subject to submission and FDA approval. The company stated that its March 31 cash and marketable securities should fund operations for at least 12 months and are expected to support operations through positive operating cash flow after a commercial launch, if approved; this depends on assumptions and outcomes.
- Management expects R&D expense to decrease in 2024 as CLARITY trials wind down, while SG&A and commercial infrastructure spending are expected to increase in preparation for a potential launch.
- The company cited CLARITY 1 and 2 results for LNZ100, including three-line-or-greater near-vision improvement in 71% of participants at 30 minutes and at three hours, and 40% at 10 hours in CLARITY 2 day-one results. It reported no serious treatment-related adverse events across more than 30,000 treatment days in the CLARITY studies. Trial outcomes do not ensure FDA approval or commercial success.
- Principal risks include dependence on LNZ100 as the sole current development candidate; FDA review and potential requirements for additional data; manufacturing and third-party supplier reliance; market adoption, pricing and competition; intellectual-property challenges; and possible need for additional financing. Management estimates a U.S. addressable presbyopia population of 128 million and a market opportunity above $3 billion; these are estimates, not realized demand.
- Two merger-related complaints alleging proxy disclosure deficiencies were voluntarily dismissed in March and April 2024. The company had also received 12 demand letters and said further actions were possible; it could not predict their outcome. No material indemnification claims or other proceedings expected to materially affect results were reported.
- After quarter-end, the company entered a 39-month lease for Solana Beach office space, commencing July 1, 2024, with monthly base rent of approximately $37,000 and annual increases of approximately 4%.
Important facts for investors to verify
- Whether the NDA was submitted on the planned mid-2024 schedule, and any FDA feedback, review timeline or additional evidence requirements.
- Final, complete CLARITY safety and efficacy data, proposed labeling, and whether FDA review supports the planned 2025 launch target.
- Cash use, commercial-preparation spending and updated runway assumptions against the stated expectation of funding through launch and subsequent positive operating cash flow.
- Commercial supply readiness, manufacturing capacity and costs, and the ability to build an effective sales and marketing organization.
- Market uptake, pricing and competitive positioning, including whether LNZ100 can demonstrate advantages that translate into sustained use.
- Any developments in merger-related demands or litigation, and the potential dilution and resale implications of merger, PIPE and equity-plan shares.